Overview

Study Comparing 4 Cycles With 6 Cycles of TC (Docetaxel+Cyclophosphamide) Adjuvant Chemotherapy for 1-3 Lymph Node Positive ER+/HER2- Early Breast Cancer

Status:
Recruiting

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

Summary

This is a prospective, multisite, randomized, open-label Phase III clinical trial (CLOVER study) comparing 4 cycles with 6 cycles of TC (docetaxel+cyclophosphamide) adjuvant chemotherapy for 1-3 positive lymph node, ER+/HER2- early breast cancer patients.

Phase:

Phase 3

Details

Lead Sponsor:

Fudan University

Treatments:

Cyclophosphamide
Docetaxel